Vera Therapeutics sets 2026 path for atacicept

Vera Therapeutics reported a key regulatory update for its drug candidate atacicept in adults with IgA nephropathy.

Rhea-AI Filing Summary

Vera Therapeutics reported a key regulatory update for its drug candidate atacicept in adults with IgA nephropathy. The company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan intended to support potential full approval.

The eGFR results from ORIGIN 3 are now expected in the third quarter of 2026. If those results are supportive, Vera plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026. The company cautions that these are forward-looking statements subject to clinical, regulatory, and broader business risks.

Positive

• Regulatory alignment with FDA on a revised ORIGIN 3 eGFR analysis plan gives a clearer framework for how atacicept data will be assessed for potential full approval in IgA nephropathy.
• Defined 2026 timeline with eGFR results expected in the third quarter of 2026 and a planned supplemental Biologics License Application submission in the fourth quarter of 2026, contingent on supportive data.

Negative

• None.

Insights

Biotech regulatory analyst

FDA alignment sets a clearer 2026 path toward potential full approval of atacicept.

Vera Therapeutics has agreed with the U.S. Food and Drug Administration on a revised ORIGIN 3 eGFR analysis plan for atacicept in IgA nephropathy. This alignment provides a defined framework for how kidney function data will be evaluated for potential full approval.

The company now expects eGFR results in Q3 2026 and, if supportive, plans a supplemental Biologics License Application in Q4 2026. These milestones are framed as forward-looking and depend on clinical outcomes and the regulatory review process, as well as broader business and macroeconomic risks described in its SEC filings.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

eGFR results timing: Q3 2026 Planned sBLA timing: Q4 2026 8-K event date: June 2, 2026

3 metrics

eGFR results timing Q3 2026 ORIGIN 3 eGFR results expected

Planned sBLA timing Q4 2026 Supplemental Biologics License Application for full approval

8-K event date June 2, 2026 Date of press release and other event

Key Terms

ORIGIN 3 eGFR analysis, supplemental Biologics License Application, IgA Nephropathy, forward-looking statements, +1 more

5 terms

ORIGIN 3 eGFR analysis medical

"aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan"

supplemental Biologics License Application regulatory

"plans to submit a supplemental Biologics License Application for full approval of atacicept"

A supplemental biologics license application is a formal request to a regulator (such as the U.S. Food and Drug Administration) asking permission to change an already approved biological product — for example to add a new use, change how it’s made, or alter dosing. For investors, an approved supplemental application can expand a product’s sales or reduce manufacturing risk, while a delay or rejection can limit revenue prospects or raise compliance costs; think of it like applying for an update to a building permit for an existing, income-producing property.

IgA Nephropathy medical

"full approval of atacicept in adults with IgA Nephropathy"

A kidney disease caused when deposits of the antibody called IgA collect in the tiny filters of the kidney, gradually reducing their ability to clear waste — like grit building up in a water filter. It matters to investors because it creates demand for diagnostics, drugs and long‑term care, drives clinical trial activity and regulatory decisions, and can influence the financial outlook of companies in pharma, biotech, medical devices and health insurance.

forward-looking statements regulatory

"Statements contained in this on regarding matters, events or results that may occur in the future are “forward-looking statements”"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

regulatory approval process regulatory

"risks related to the regulatory approval process, results of earlier clinical trials may not be obtained"

The regulatory approval process is the sequence of government reviews, tests and documentation a product—commonly a drug, medical device or other regulated offering—must clear before it can be sold or marketed. For investors it matters because approval is the gate that turns research into revenue: passing it can unlock large sales, while delays, additional requirements or rejection can add costs, push back timelines and sharply reduce a company’s value, much like waiting for a building permit before you can occupy a new property.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vera Therapeutics (VERA) announce about atacicept and the FDA?

Vera Therapeutics announced it has aligned with the U.S. Food and Drug Administration on a revised ORIGIN 3 eGFR analysis plan. This plan is intended to support potential full approval of atacicept in adults with IgA nephropathy if upcoming trial results are favorable.

When are the ORIGIN 3 eGFR results for Vera Therapeutics’ atacicept expected?

The eGFR results from the ORIGIN 3 study are now expected in the third quarter of 2026. These kidney function data are intended to form a key part of the evidence package supporting potential full approval of atacicept for adults with IgA nephropathy.

When does Vera Therapeutics plan to submit the supplemental BLA for atacicept?

Vera Therapeutics plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026. This timing is contingent on the ORIGIN 3 eGFR results being supportive of full approval in adults with IgA nephropathy.

What indication is Vera Therapeutics targeting for atacicept approval?

Vera Therapeutics is targeting full approval of atacicept in adults with IgA nephropathy. The revised ORIGIN 3 eGFR analysis plan and planned supplemental Biologics License Application are specifically aimed at supporting this indication, pending favorable kidney function results in 2026.

What risks does Vera Therapeutics highlight regarding atacicept’s potential approval?

Vera Therapeutics notes risks related to the regulatory approval process, that earlier trial results may not be replicated, and that preliminary data may not predict topline outcomes. It also cites general business, macroeconomic, geopolitical, and other risks described in its SEC filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 07:05 AM Learn about SEC filing dates

false000183182800018318282026-06-022026-06-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 02, 2026

Vera Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40407	81-2744449
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 1200
Brisbane, California				94005
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 770-0077

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, $0.001 par value per share		VERA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 2, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential full approval of atacicept in adults with IgA Nephropathy. The eGFR results are now expected in the third quarter of 2026. Pending these results, the Company plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026.

Forward Looking Statements

Statements contained in this Current Report on Form 8-K regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about the Company’s expectations regarding the approval of atacicept by the U.S. Food and Drug Administration, the timing of eGFR results, and the submission by the Company of a supplemental Biologics License Application for full approval of atacicept as well as the timing of such submission. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expects,” “plans,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with the Company’s business in general, the impact of macroeconomic and geopolitical events and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Vera Therapeutics, Inc.
Date:	June 2, 2026	By:	/s/ Marshall Fordyce
			Marshall Fordyce, M.D. Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.4 KB